Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 7/20 | 0.41 |
| ▸ | IKBKB | O14920 | 7/20 | 0.38 |
| ▸ | CHUK | O15111 | 7/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237740 | 0.84 | BRD4 (0.40) | IKBKBCHUKBRD4BRAFTHRB | |
| SCHEMBL2239926 | 0.84 | IKBKB (0.48) | IKBKBCHUKMAPK8 | |
| SCHEMBL13521527 | 0.79 | ATR (0.35) | IKBKBCHUKABL1SRCPIK3CD | |
| SCHEMBL1839697 | 0.78 | NEK1 (0.48) | NEK1IKBKBCHUKBRD4ROCK1 | |
| SCHEMBL2321083 | 0.73 | BRD4 (0.42) | IKBKBCHUKBRD4ABL1PIK3CD | |
| SCHEMBL2240276 | 0.67 | MAOA (0.43) | IKBKBCHUKBRD4 | |
| SCHEMBL13014033 | 0.67 | IKBKB (0.56) | NEK1IKBKBCHUKROCK1 | |
| SCHEMBL2316724 | 0.66 | SYK (0.42) | — | |
| SCHEMBL3414036 | 0.65 | IKBKB (0.46) | NEK1IKBKBCHUKROCK1 | |
| SCHEMBL1779946 | 0.65 | MAPT (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | NEK1 349/4885IKBKB 246/4885CHUK 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.